Navigation Links
Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
Date:8/20/2008

MONTREAL, Aug. 20 /PRNewswire/ -- Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, today announced that the first patient in its clinical program for hypophosphatasia has been dosed. Enobia is investigating Enzyme Replacement Therapy (ERT) with ENB-0040 for the treatment of this rare and often crippling genetic bone disorder for which there is no approved treatment.

Under two separate protocols, ENB-0040 will be evaluated in both adults and infants afflicted with hypophosphatasia in Canada and the USA. "This may well be a milestone in the treatment of hypophosphatasia," said Michael Whyte, MD, Professor of Medicine at Washington University School of Medicine, St. Louis, MO, and consultant to Enobia Pharma. "Studies in a mouse model for hypophosphatasia show ENB-0040 has the potential to greatly enhance the quality-of-life for patients."

Under the first protocol, safety, tolerability and pharmacokinetics of ENB-0040 will be evaluated for one month in an open-label, dose escalation Phase I study of ENB-0040 delivered intravenously and subcutaneously to six adults with hypophosphatasia at three North American sites.

Under the second protocol, safety, tolerability, pharmacokinetics, and efficacy of ENB-0040 will also be evaluated in a six-month open label study of up to six infants with particularly severe hypophosphatasia. Key efficacy outcomes include assessment of skeletal and respiratory manifestations of the disease.

"In preclinical studies using a mouse model, ENB-0040 consistently improved survival as well as bone and dental manifestations of hypophosphatasia. The initiation of clinical studies brings us closer to the goal of providing drug therapy for hypophosphatasia patients where none currently exists," stated Robert Heft, PhD, Chief Executive Officer of Enobia.

About Hypophosphatasia

Hypophosphatasia is a rare, inherited, and sometimes fatal metabo
'/>"/>

SOURCE Enobia Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
2. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
3. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
4. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
5. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
6. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
7. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
8. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
10. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
11. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015 Today, humanity takes a ... the singularity, and fat-free cronuts: 1-800 CONTACTS announces their new ... in just two taps. Two taps. New contacts. ... The app also features LensGauge which helps keep ... when you need to reorder. "Since our inception, ...
(Date:4/24/2015)... April 24, 2015  A new study shows an "alarming ... drugs used to slow the progression of multiple sclerosis or ... by researchers at Oregon Health & Science University (OHSU) and ... the number of MS drugs in the marketplace over the ... stabilized costs for patients who use those drugs. Researchers found ...
(Date:4/24/2015)... S.C. , April 24, 2015  Span-America ... plans to release its fiscal 2015 second quarter ... regular trading. The company will conduct ... Friday, May 1, to review the company,s financial and ... 2015.  A live broadcast of the conference call ...
Breaking Medicine Technology:Attention: We live in the future. Order contact lenses from your wrist with the 1-800 CONTACTS app for Apple Watch 2Researchers find alarming rise in cost of MS drugs over past two decades 2Researchers find alarming rise in cost of MS drugs over past two decades 3Researchers find alarming rise in cost of MS drugs over past two decades 4
... influenza,transmission patterns in the Southern Hemisphere and ... finding that,each season influenza travels from low ... populated centers. Their work, funded by the,Fogarty ... Institutes,of Health (NIH), can improve planning for ...
... - An overexpressed protein,protects human pancreatic cancer ... of the body's natural defenses against,out-of-control cell growth, ... Cancer Center report in the March issue of ... by the abbreviation,TG2, previously has been found by ...
Cached Medicine Technology:Researchers Find Surprising Pattern of Influenza Spread in South,America and Tropics 2Researchers Find Surprising Pattern of Influenza Spread in South,America and Tropics 3Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 2Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 3
(Date:4/25/2015)... 25, 2015 By definition, a CIO’s responsibility ... the enterprise relying on their judgement and expertise to keep ... according to an article published in National Mortgage News ... be doing a disservice to their responsibilities by focusing too ... t’s are crossed when it comes to company policy and ...
(Date:4/25/2015)... (PRWEB) April 25, 2015 Parker and Sons ... and cooling, has spiked in Arizona alongside the growing economy. ... additional forty employees for April to help account for the ... forty employees in April is something we are enthusiastic about. ... said Paul Kelly, president at Parker and Sons. , Indeed, ...
(Date:4/25/2015)... For thirteen years, the Twin Cities DI ... event in the nation! This year, on May 5th, 2015, ... to take DI Day on the road by supporting the ... ChFC, RHU, DIA, CLTC, Chief Executive Officer at Secura Consultants ... the change by stating, "The first Twin Cities DI Day ...
(Date:4/24/2015)... 24, 2015 As the nation recognizes ... unique sacrifices of these young men and women, the ... Veterans and their Families” presents a special training session ... to gain a better understanding of the effect of ... For those – civilian and military – who provide ...
(Date:4/24/2015)... 2015 Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ... federal multidistrict litigation underway in U.S. District Court, ... the parties involved in the proceeding submitted a ... other things, preparation for the litigation’s upcoming bellwether ... plaintiffs and defendants have conducted depositions of non-party ...
Breaking Medicine News(10 mins):Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Parker and Sons Plans to Expand in 2015 2Health News:Secura Consultants Takes DI Day On The Road 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3
... transplants after removing small cancerous and benign masses from ... December issue of the urology journal BJUI. The ... of Maryland School of Medicine in Baltimore, could offer ... as well as increasing the supply of viable organs. ...
... Nutra Pharma ... the Food and Drug Administration (FDA). This registration is considered the final step required by ... the treatment of chronic pain. , ... Plantation, FL (Vocus) December 7, 2009 -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology ...
... ... Changes in Industry Standards and Compliance Requirements , ... (PRWEB) December 7, 2009 -- BridgeGate ... the launch of its new integration technology training program, which will kick off ...
... in comparison study , SUNDAY, Dec. 6 (HealthDay ... therapy for prostate cancer are best controlled by ... according to a new study. , Androgen suppression ... prostate cancer, but about 80 percent of patients ...
... older anti-clotting drug, with fewer hassles, study finds , MONDAY, ... dabigatran etexilate may be just as effective in preventing dangerous ... for doctors and patients to manage, a new study finds. ... in Europe; it is not yet approved for use in ...
... ... offer top-of-the-line implementation services to Talyst’s clients in the acute care industry. ... (PRWEB) ... of the American Society of Health-System Pharmacists in Las Vegas, Talyst announced a ...
Cached Medicine News:Health News:Controversial kidney transplant technique could provide lifeline for very ill patients 2Health News:Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain 2Health News:Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain 3Health News:BridgeGate International Announces New Integration and Interoperability Training Program 2Health News:BridgeGate International Announces New Integration and Interoperability Training Program 3Health News:BridgeGate International Announces New Integration and Interoperability Training Program 4Health News:Hormonal Drugs Cool Hot Flashes From Prostate Cancer Therapy 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3Health News:Talyst and RXinnovate Partner on Pharmacy Automation Implementation 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: